<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05117372</url>
  </required_header>
  <id_info>
    <org_study_id>2020-A01626-33</org_study_id>
    <nct_id>NCT05117372</nct_id>
  </id_info>
  <brief_title>ANALYSIS OF INFLAMMATORY REACTIONS OBSERVED IN BRONCHOALVEOLAR LAVAGES (BALS)</brief_title>
  <acronym>LBA-PI</acronym>
  <official_title>ANALYSIS OF INFLAMMATORY REACTIONS OBSERVED IN BRONCHOALVEOLAR LAVAGES (BALS) PERFORMED FOR INFILTRATIVE LUNG DISEASE THAT COMPLICATE ANTI PD-(L)1 IMMUNOTHERAPIES</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Chirurgical Marie Lannelongue</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Chirurgical Marie Lannelongue</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Immunological toxicities associated with immune checkpoint inhibitor (ICI) monoclonal&#xD;
      antibodies are unpredictable autoimmune and inflammatory pathologies that can affect all&#xD;
      treated patients. Some of these events are severe and occur in 15-20% of patients treated&#xD;
      with Programmed Death 1 (PD-1) antibodies.&#xD;
&#xD;
      The study of cellular immunological characteristics within tissues affected by toxicities and&#xD;
      the interactions between the different actors of these toxicities aims at improving the&#xD;
      knowledge concerning the mechanisms of these toxicities, but also at being able to specify&#xD;
      the unexpected effects of ICIs on cells of the immune system, outside the tumor&#xD;
      microenvironment.&#xD;
&#xD;
      Diffuse infiltrative lung disease is one of the most frequent and severe toxicities&#xD;
      encountered in patients treated with anti PD-(L)1; either for bronchial cancer, melanoma or&#xD;
      any other type of cancer. Patients developing this type of complication benefit from&#xD;
      cytological, bacteriological, mycological and molecular analyses of intra-alveolar&#xD;
      constituents obtained by bronchoalveolar lavage (BAL) performed during bronchial fibroscopy&#xD;
      as part of their routine care. These analyses help to confirm the diagnosis of alveolitis, to&#xD;
      specify the cellular characteristics of alveolar inflammation and to eliminate differential&#xD;
      diagnoses of ICI toxicity.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 17, 2021</start_date>
  <completion_date type="Anticipated">February 17, 2024</completion_date>
  <primary_completion_date type="Anticipated">August 17, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Expression levels of cellular and soluble actors involved in the occurrence of pulmonary toxicities associated with antitumor immunotherapies</measure>
    <time_frame>1 day</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">34</enrollment>
  <condition>Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Patients treated with with immunotherapy and developing diffuse infiltrative lung disease</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group 1: Patients treated for cancer with immunotherapy and developing diffuse infiltrative lung disease</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients not treated with immunotherapy and requiring carcinologic lobectomy</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Group 2: Patients with lung cancer not treated with immunotherapy and requiring carcinologic lobectomy</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>treatment with immunotherapy and diffuse infiltrative lung disease</intervention_name>
    <description>Patients treated with with immunotherapy and developing diffuse infiltrative lung disease</description>
    <arm_group_label>Patients treated with with immunotherapy and developing diffuse infiltrative lung disease</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Patients requiring carcinologic lobectomy</intervention_name>
    <description>Patients requiring carcinologic lobectomy</description>
    <arm_group_label>Patients not treated with immunotherapy and requiring carcinologic lobectomy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult subject (≥ 18 years old)&#xD;
&#xD;
          -  Patient having consented to the research&#xD;
&#xD;
        Group 1:&#xD;
&#xD;
          -  Patient with cancer who was treated with immunotherapy&#xD;
&#xD;
          -  Appearance of CT lung abnormalities during immunotherapy, not related to cancer&#xD;
&#xD;
          -  With high suspicion of infiltrative lung disease:&#xD;
&#xD;
          -  Pneumopathy (CTCAE version 5 classification).&#xD;
&#xD;
          -  Patients requiring bronchial fibroscopy with BAL&#xD;
&#xD;
        Groups 2:&#xD;
&#xD;
          -  Patient with lung cancer with peripheral tumor&#xD;
&#xD;
          -  Requires surgical pulmonary lobectomy in the operating room&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient treated or having been treated in the last 2 months with corticosteroid&#xD;
             therapy&#xD;
&#xD;
          -  Patient treated with immunosuppressant and/or cyclophosphamide, and/or Anti-TNF α in&#xD;
             the last 12 months&#xD;
&#xD;
          -  Absence of consent&#xD;
&#xD;
          -  Patient under curatorship, guardianship or safeguard of justice&#xD;
&#xD;
          -  Pregnant woman&#xD;
&#xD;
          -  Group 1:&#xD;
&#xD;
          -  Patient with respiratory failure&#xD;
&#xD;
        Groups 2:&#xD;
&#xD;
          -  Patient with lung cancer with proximal or endobronchial tumor&#xD;
&#xD;
          -  Patients requiring bilobectomy or pneumonectomy&#xD;
&#xD;
          -  Patient who has been treated with immunotherapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jérôme LE PAVEC, MD</last_name>
    <phone>01.40.94.24.30</phone>
    <email>J.lepavec@ghpsj.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Centre Chirurgical Marie Lannelongue</name>
      <address>
        <city>Le Plessis Robinson</city>
        <zip>92350</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 6, 2021</study_first_submitted>
  <study_first_submitted_qc>November 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 11, 2021</study_first_posted>
  <last_update_submitted>November 2, 2021</last_update_submitted>
  <last_update_submitted_qc>November 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>anti PD-(L)1</keyword>
  <keyword>Diffuse infiltrative lung disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

